Me! I Disconnect From You

Efficacy and Tolerability of Glimepiride in Daily Training: A Non-Interventional Observational Lot Field
from Clinical Drug Inquiry [TM] Posted 09/01/2001
Gerhard H.
Scholz , Medizinische Klinik und Poliklinik III, Universitat Leipzig, Leipzig, Germany; Kerstin Schneider , Wolfgang Knirsch , Gerhard Becker , Aventis Pharma Deutschland GmbH, BU Diabetologie, Bad Soden am Taunus, Germany
Conception and Institution Construct Aim: The aim of the gift concentration was to proctor the efficacy and tolerability of glimepiride in daily knowledge. Purpose: An 8-week non-interventional circle contemplation investigating glimepiride in daily preparation. Environment and Data Accumulation: 4810 fact practitioners and medical building physicians were asked to noise on demographics and medical account, glimepiride dose, glycated haemoglobin (HbA1c) levels, adverse events and causes of discontinuation of therapy. Patients: 22 045 patients with type 2 diabetes mellitus pretreated with anti-hyperglycaemic drugs excluding glimepiride and patients not treated with any antihyperglycaemic drug or treated with diet alone.
Most patients were either overweight (42.2%) or obese (26.1%). Results: A amount of 29.3% of patients were treated with glimepiride as a first-time antihyperglycaemic drug, whereas in 70.7% of patients pre-existing oral anti-hyperglycaemic medicinal drug was changed to amaryl monotherapy (69.6%) or continued as aggregation therapy with glimepiride (30.4%).
The initial and final examination doses were lower in patients who commenced oral antihyperglycaemic therapy (initial 1.3mg, match 1.8mg) compared with patients whose therapy was changed (initial 1.7mg, match 2.4mg).
The mean diminution of HbA1c was more pronounced in newly treated patients (1.8%) compared with patients changed to glimepiride therapy (1.3%).
This is a part of article Efficacy and Tolerability of Glimepiride in Daily Practice: A Non-Interventional Observational Cohort Study Taken from "Generic Amaryl (Glimepiride) Information" Information Blog

Labels: pharmacology

# posted by Haig Aglaia @ 6:05 AM